Outcomes of Refractory Metastatic Colorectal Cancer Patients Treated with Regorafenib and Trifluridine / Tipiracil as Late Line Treatment

Abstract

We retrospectively analyzed the clinical outcomes of unresectable metastatic colorectal cancer patients who received late-line therapy. We collected medical records data from 41 patients who underwent late-line treatment with regorafenib and / or trifluridine / tipiracil (TFTD) between July 2013 and December 2016. There were no significant differences in overall survival and progression-free survival of patients who first received regorafenib (n=25) vs. those who first received TFTD (n=16). Nineteen patients who received both of regorafenib and TFTD experienced significantly longer overall survival than 22 patients who only received one drug (median: 20.8 months vs. 6.4 months, p= 0.02). Our data suggest that administration of both regorafenib and TFTD as late-line chemotherapy for colorectal cancer may prolong patient survival times.